Recent Publications

• 1. Simpson EL
  2. De Benedetto A
  3. Boguniewicz M
  4. Ong PY
  5. Lussier S
  6. Villarreal M
  7. Schneider LC
  8. Paller AS
  9. Guttman-Yassky E
  10. Hanifin JM
  11. Spergel JM
  12. Barnes KC
  13. David G
  14. Austin B
  15. Leung DYM
  16. Beck LA
  Phenotypic and Endotypic Determinants of Atopic Dermatitis Severity from the ADRN Registry.; The journal of allergy and clinical immunology. In practice. 2023 May 12.
• 1. Moran MC
  2. Chinchilli E
  3. Kenney HM
  4. Pope EM
  5. Scott G
  6. Brewer MG
  7. Beck LA
  Stage of Keratinocyte Differentiation is a Key Determinant of Viral Susceptibility in Human Skin.; The Journal of investigative dermatology. 2023 Mar 28.
• 1. Zuberbier T
  2. Beck LA
  3. Bedbrook A
  4. de Bruin-Weller M
  5. Bousquet J
  6. Cork M
  7. Douladiris N
  8. Katoh N
  9. Mortz CG
  10. Werfel T
  11. Wojciech F
  12. Wollenberg A
  13. Siemens K
  14. Stevanovic K
  15. Worm M
  Developing integrated care pathways for atopic dermatitis-Challenges and unmet needs.; Clinical and translational allergy; Vol 13(3), pp. e12236. 2023 Mar.
• 1. Smith HD
  2. Williams B
  3. Beck LA
  4. De Benedetto A
  Erythema Multiforme Secondary to Poison Ivy Contact Dermatitis.; Dermatitis : contact, atopic, occupational, drug. 2023 Feb 27.
• 1. Yang B
  2. Wilkie H
  3. Das M
  4. Timilshina M
  5. Bainter W
  6. Woods B
  7. Daya M
  8. Boorgula MP
  9. Mathias RA
  10. Lai P
  11. Petty CR
  12. Weller E
  13. Harb H
  14. Leung DYM
  15. Beck LA
  16. Simpson EL
  17. Hata TR
  18. Barnes KC
  19. Phipatanakul W
  20. Leyva-Castillo JM
  21. Geha RS
  The IL-4Rα Q576R polymorphism is associated with increased severity of atopic dermatitis and exaggerates allergic skin inflammation in mice.; The Journal of allergy and clinical immunology. 2023 Jan 20.
• 1. Schlievert PM
  2. Kilgore SH
  3. Beck LA
  4. Yoshida T
  5. Klingelhutz AJ
  6. Leung DYM
  Host Cationic Antimicrobial Molecules Inhibit S. aureus Exotoxin Production.; mSphere. 2023 Jan 04.
• 1. Moran MC
  2. Pope EM
  3. Brewer MG
  4. Beck LA
  Supply Chain Disruptions During COVID Pandemic Uncover Differences in Keratinocyte Culture Media.; JID innovations : skin science from molecules to population health. 2022 Aug 22.
• 1. Paller AS
  2. Beck LA
  Bleach baths for atopic dermatitis: Evidence of efficacy but more data are needed.; Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology; Vol 128(6). 2022 Jun.
• 1. Beck LA
  2. Deleuran M
  3. Bissonnette R
  4. de Bruin-Weller M
  5. Galus R
  6. Nakahara T
  7. Seo SJ
  8. Khokhar FA
  9. Vakil J
  10. Xiao J
  11. Marco AR
  12. Levit NA
  13. O'Malley JT
  14. Shabbir A
  Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.; American journal of clinical dermatology. 2022 May 03.
• 1. Beck LA
  2. Cork MJ
  3. Amagai M
  4. De Benedetto A
  5. Kabashima K
  6. Hamilton JD
  7. Rossi AB
  Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis.; JID innovations : skin science from molecules to population health; Vol 2(5), pp. 100131. 2022 Apr 26.
• 1. Brewer MG
  2. Monticelli SR
  3. Moran MC
  4. Miller BL
  5. Beck LA
  6. Ward BM
  Conditions That Simulate the Environment of Atopic Dermatitis Enhance Susceptibility of Human Keratinocytes to Vaccinia Virus.; Cells; Vol 11(8). 2022 Apr 14.
• 1. Pope EM
  2. Laageide L
  3. Beck LA
  Management of Allergic Skin Disorders in Pregnancy.; Immunology and allergy clinics of North America; Vol 43(1), pp. 117-132. 2022 Jan 28.
• 1. Paller AS
  2. Beck LA
  3. Blauvelt A
  4. Siegfried EC
  5. Cork MJ
  6. Wollenberg A
  7. Chen Z
  8. Khokhar FA
  9. Vakil J
  10. Zhang A
  11. Bansal A
  12. Cyr SL
  Infections in children and adolescents treated with dupilumab in pediatric clinical trials for atopic dermatitis-A pooled analysis of trial data.; Pediatric dermatology. 2022 Jan 26.
• 1. Beck LA
  2. Pesonen M
  3. Thakar J
  4. Georas SN
  5. Järvinen KM
  IgE Sensitization Drives the Atopic March.; American journal of respiratory and critical care medicine. 2022 Jan 08.
• 1. Beck LA
  2. Bieber T
  3. Weidinger S
  4. Tauber M
  5. Saeki H
  6. Irvine AD
  7. Eichenfield LF
  8. Werfel T
  9. Arlert P
  10. Jiang L
  11. Røpke M
  12. Paller AS
  Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate-to-severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial.; Journal of the American Academy of Dermatology. 2022 Jan 03.
• 1. Herman KE
  2. Yoshida T
  3. Hughson A
  4. Grier A
  5. Gill SR
  6. Beck LA
  7. Fowell DJ
  IL-17-Dependent Dysregulated Cutaneous Immune Homeostasis in the Absence of the Wiskott-Aldrich Syndrome Protein.; Frontiers in immunology; Vol 13. 2022.
• 1. Yoshida T
  2. Beck LA
  3. De Benedetto A
  Skin barrier defects in atopic dermatitis: From old idea to new opportunity.; Allergology international : official journal of the Japanese Society of Allergology. 2021 Dec 13.
• 1. Tuttle KL
  2. Forman J
  3. Beck LA
  Novel systemic treatments in atopic dermatitis: Are there sex differences?; International journal of women's dermatology; Vol 7(5Part A). 2021 Dec.
• 1. Wollenberg A
  2. Beck LA
  3. de Bruin Weller M
  4. Simpson EL
  5. Imafuku S
  6. Boguniewicz M
  7. Zachariae R
  8. Olsen CK
  9. Thyssen JP
  Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.; The British journal of dermatology. 2021 Oct 12.
• 1. Daya M
  2. Cox C
  3. Acevedo N
  4. Boorgula MP
  5. Campbell M
  6. Chavan S
  7. Cho MH
  8. David GL
  9. Kachroo P
  10. Lasky-Su J
  11. Li X
  12. McHugh CP
  13. Qiao D
  14. Rafaels N
  15. Beck LA
  16. Bleecker ER
  17. Caraballo L
  18. Cupples AL
  19. Figueiredo CA
  20. Gallo RL
  21. Hanifin J
  22. Hansel NN
  23. Hata TR
  24. Hersh CP
  25. Knight-Madden J
  26. Leung DYM
  27. Guttman-Yassky E
  28. Meyers DA
  29. O'Connor G
  30. Ober C
  31. Ong PY
  32. Ortega VE
  33. Paller AS
  34. Putcha N
  35. Reed RM
  36. Schneider LC
  37. Silverman EK
  38. Slifka MK
  39. Spergel JM
  40. Vasan RS
  41. Viaud-Martinez KA
  42. Watson H
  43. Weiss ST
  44. Ruczinski I
  45. Beaty TH
  46. Mathias RA
  47. Barnes KC
  Multi-ethnic genome-wide and HLA association study of total serum IgE.; The Journal of allergy and clinical immunology. 2021 Sep 15.
• 1. Arehart CH
  2. Daya M
  3. Campbell M
  4. Boorgula MP
  5. Rafaels N
  6. Chavan S
  7. David G
  8. Hanifin J
  9. Slifka MK
  10. Gallo RL
  11. Hata T
  12. Schneider LC
  13. Paller AS
  14. Ong PY
  15. Spergel JM
  16. Guttman-Yassky E
  17. Leung DYM
  18. Beck LA
  19. Gignoux CR
  20. Mathias RA
  21. Barnes KC
  Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors.; The Journal of allergy and clinical immunology. 2021 Jun 07.
• 1. Moran MC
  2. Pandya RP
  3. Leffler KA
  4. Yoshida T
  5. Beck LA
  6. Brewer MG
  Characterization of Human Keratinocyte Cell Lines for Barrier Studies.; JID innovations; Vol 1(2). 2021 Jun.
• 1. Siegfried EC
  2. Bieber T
  3. Simpson EL
  4. Paller AS
  5. Beck LA
  6. Boguniewicz M
  7. Schneider LC
  8. Khokhar FA
  9. Chen Z
  10. Prescilla R
  11. Mina-Osorio P
  12. Bansal A
  Effect of Dupilumab on Laboratory Parameters in Adolescents with Atopic Dermatitis: Results from a Randomized, Placebo-Controlled, Phase 3 Clinical Trial.; American journal of clinical dermatology. 2021 Mar 03.
• 1. Mahadevan N
  2. Christakis Y
  3. Di J
  4. Bruno J
  5. Zhang Y
  6. Dorsey ER
  7. Pigeon WR
  8. Beck LA
  9. Thomas K
  10. Liu Y
  11. Wicker M
  12. Brooks C
  13. Kabiri NS
  14. Bhangu J
  15. Northcott C
  16. Patel S
  Development of digital measures for nighttime scratch and sleep using wrist-worn wearable devices.; NPJ digital medicine; Vol 4(1). 2021 Mar 03.
• 1. Beck LA
  2. Thaçi D
  3. Deleuran M
  4. de Bruin-Weller M
  5. Chen Z
  6. Khokhar FA
  7. Zhang M
  8. Ozturk ZE
  9. Shumel B
  Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study.; The Journal of dermatological treatment. 2021 Feb 08.
• 1. Bin L
  2. Malley C
  3. Taylor P
  4. PreethiBoorgula M
  5. Chavan S
  6. Daya M
  7. Mathias M
  8. Shankar G
  9. Rafaels N
  10. Vergara C
  11. Potee J
  12. Campbell M
  13. Hanifin JM
  14. Simpson E
  15. Schneider LC
  16. Gallo RL
  17. Hata T
  18. Paller AS
  19. De Benedetto A
  20. Beck LA
  21. Ong PY
  22. Guttman-Yassky E
  23. Richers B
  24. Baraghoshi D
  25. Ruczinski I
  26. Barnes K
  27. Leung DYM
  28. Mathias RA
  Whole genome sequencing identifies novel genetic mutations in patients with eczema herpeticum.; Allergy. 2021 Feb 06.
• 1. Boguniewicz M
  2. Beck LA
  3. Sher L
  4. Guttman-Yassky E
  5. Thaçi D
  6. Blauvelt A
  7. Worm M
  8. Corren J
  9. Soong W
  10. Lio P
  11. Rossi AB
  12. Lu Y
  13. Chao J
  14. Eckert L
  15. Gadkari A
  16. Hultsch T
  17. Ruddy M
  18. Mannent LP
  19. Graham NMH
  20. Pirozzi G
  21. Chen Z
  22. Ardeleanu M
  Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate-to-Severe Atopic Dermatitis.; The journal of allergy and clinical immunology. In practice. 2021 Jan 13.
• 1. Bawany F
  2. Northcott CA
  3. Beck LA
  4. Pigeon WR
  Sleep Disturbances and Atopic Dermatitis: Relationships, Methods for Assessment, and Therapies.; The journal of allergy and clinical immunology. In practice. 2020 Dec 12.
• 1. Bawany F
  2. Franco AI
  3. Beck LA
  Dupilumab: One therapy to treat multiple atopic diseases.; JAAD case reports; Vol 6(11). 2020 Nov.
• 1. Beck LA
  2. Silverberg JI
  3. Simpson EL
  4. Yosipovitch G
  5. Eckert L
  6. Guillemin I
  7. Chen Z
  8. Ardeleanu M
  9. Plaum S
  10. Graham N
  11. Ruddy M
  12. Pirozzi G
  13. Gadkari A
  Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials.; Journal of the European Academy of Dermatology and Venereology : JEADV. 2020 Aug 12.
• 1. Paller AS
  2. Siegfried EC
  3. Thaçi D
  4. Wollenberg A
  5. Cork MJ
  6. Arkwright PD
  7. Gooderham M
  8. Beck LA
  9. Boguniewicz M
  10. Sher L
  11. Weisman J
  12. O'Malley JT
  13. Patel N
  14. Hardin M
  15. Graham NMH
  16. Ruddy M
  17. Sun X
  18. Davis JD
  19. Kamal MA
  20. Khokhar FA
  21. Weinreich DM
  22. Yancopoulos GD
  23. Beazley B
  24. Bansal A
  25. Shumel B
  Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial.; Journal of the American Academy of Dermatology. 2020 Jun 20.
• 1. Beck LA
  2. Thaçi D
  3. Deleuran M
  4. Blauvelt A
  5. Bissonnette R
  6. de Bruin-Weller M
  7. Hide M
  8. Sher L
  9. Hussain I
  10. Chen Z
  11. Khokhar FA
  12. Beazley B
  13. Ruddy M
  14. Patel N
  15. Graham NMH
  16. Ardeleanu M
  17. Shumel B
  Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.; American journal of clinical dermatology. 2020 Jun 17.
• 1. Wollenberg A
  2. Beck LA
  3. Blauvelt A
  4. Simpson EL
  5. Chen Z
  6. Chen Q
  7. Shumel B
  8. Khokhar FA
  9. Hultsch T
  10. Rizova E
  11. Rossi AB
  12. Graham NMH
  13. Pirozzi G
  14. Lu Y
  15. Ardeleanu M
  Assessing the need for routine safety testing for patients being treated with dupilumab for moderate-to-severe atopic dermatitis.; The British journal of dermatology; Vol 182(6). 2020 Jun.
• 1. Moran MC
  2. Beck LA
  3. Richardson CT
  A Spectrum of Skin Disease: How Staphylococcus aureus Colonization, Barrier Dysfunction, and Cytokines Shape the Skin.; The Journal of investigative dermatology; Vol 140(5). 2020 May.
• 1. Simpson E
  2. Bissonnette R
  3. Eichenfield LF
  4. Guttman E
  5. King B
  6. Silverberg JI
  7. Beck LA
  8. Bieber T
  9. Reich K
  10. Kabashima K
  11. Seyger M
  12. Siegfried E
  13. Stingl G
  14. Feldman SR
  15. Menter A
  16. van de Kerkhof P
  17. Yosipovitch G
  18. Paul C
  19. Martel P
  20. Dubost-Brama A
  21. Armstrong J
  22. Chavda R
  23. Frey S
  24. Joubert Y
  25. Milutinovic M
  26. Parneix A
  27. Teixeira HD
  28. Lin CY
  29. Sun L
  30. Klekotka P
  31. Nickoloff B
  32. Dutronc Y
  33. Mallbris L
  34. Janes JM
  35. DeLozier AM
  36. Nunes F
  37. Paller AS
  The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.; Journal of the American Academy of Dermatology. 2020 Apr 25.
• 1. Wieser JK
  2. Kuehn GJ
  3. Prezzano JC
  4. Cusick EH
  5. Stiegler JD
  6. Scott GA
  7. Liesveld JL
  8. Beck LA
  Improvement in a patient with hypereosinophilic syndrome after initiation of dupilumab treatment.; JAAD case reports; Vol 6(4). 2020 Apr.
• 1. Platts-Mills TAE
  2. Commins SP
  3. Biedermann T
  4. van Hage M
  5. Levin M
  6. Beck LA
  7. Diuk-Wasser M
  8. Jappe U
  9. Apostolovic D
  10. Minnicozzi M
  11. Plaut M
  12. Wilson JM
  On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy.; The Journal of allergy and clinical immunology; Vol 145(4). 2020 Apr.
• 1. Bawany F
  2. Beck LA
  3. Järvinen KM
  Halting the March: Primary Prevention of Atopic Dermatitis and Food Allergies.; The journal of allergy and clinical immunology. In practice; Vol 8(3). 2020 Mar.
• 1. Guttman-Yassky E
  2. Thaçi D
  3. Pangan AL
  4. Hong HC
  5. Papp KA
  6. Reich K
  7. Beck LA
  8. Mohamed MF
  9. Othman AA
  10. Anderson JK
  11. Gu Y
  12. Teixeira HD
  13. Silverberg JI
  Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.; The Journal of allergy and clinical immunology; Vol 145(3). 2020 Mar.
• 1. Simpson EL
  2. Lacour JP
  3. Spelman L
  4. Galimberti R
  5. Eichenfield LF
  6. Bissonnette R
  7. King BA
  8. Thyssen JP
  9. Silverberg JI
  10. Bieber T
  11. Kabashima K
  12. Tsunemi Y
  13. Costanzo A
  14. Guttman-Yassky E
  15. Beck LA
  16. Janes JM
  17. DeLozier AM
  18. Gamalo M
  19. Brinker DR
  20. Cardillo T
  21. Nunes FP
  22. Paller AS
  23. Wollenberg A
  24. Reich K
  Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials.; The British journal of dermatology. 2020 Jan 05.
• 1. Worm M
  2. Simpson EL
  3. Thaçi D
  4. Bissonnette R
  5. Lacour JP
  6. Beissert S
  7. Kawashima M
  8. Ferrándiz C
  9. Smith CH
  10. Beck LA
  11. Chan KC
  12. Chen Z
  13. Akinlade B
  14. Hultsch T
  15. Staudinger H
  16. Gadkari A
  17. Eckert L
  18. Davis JD
  19. Rajadhyaksha M
  20. Graham NMH
  21. Pirozzi G
  22. Stahl N
  23. Yancopoulos GD
  24. Ardeleanu M
  Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.; JAMA dermatology. 2019 Dec 26.
• 1. Moran MC
  2. Cahill MP
  3. Brewer MG
  4. Yoshida T
  5. Knowlden S
  6. Perez-Nazario N
  7. Schlievert PM
  8. Beck LA
  Staphylococcal Virulence Factors on the Skin of Atopic Dermatitis Patients.; mSphere; Vol 4(6). 2019 Dec 11.
• 1. Simpson EL
  2. Paller AS
  3. Siegfried EC
  4. Boguniewicz M
  5. Sher L
  6. Gooderham MJ
  7. Beck LA
  8. Guttman-Yassky E
  9. Pariser D
  10. Blauvelt A
  11. Weisman J
  12. Lockshin B
  13. Hultsch T
  14. Zhang Q
  15. Kamal MA
  16. Davis JD
  17. Akinlade B
  18. Staudinger H
  19. Hamilton JD
  20. Graham NMH
  21. Pirozzi G
  22. Gadkari A
  23. Eckert L
  24. Stahl N
  25. Yancopoulos GD
  26. Ruddy M
  27. Bansal A
  Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.; JAMA dermatology. 2019 Nov 06.
• 1. Alexander H
  2. Paller AS
  3. Traidl-Hoffmann C
  4. Beck LA
  5. De Benedetto A
  6. Dhar S
  7. Girolomoni G
  8. Irvine AD
  9. Spuls P
  10. Su J
  11. Thyssen JP
  12. Vestergaard C
  13. Werfel T
  14. Wollenberg A
  15. Deleuran M
  16. Flohr C
  The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group.; The British journal of dermatology. 2019 Nov 01.
• 1. Matson CC
  2. Beck LA
  3. Rajasekaran SK
  Using Language That Reflects Who Is the Center of Our Care.; Academic medicine : journal of the Association of American Medical Colleges; Vol 94(9). 2019 Sep.
• 1. Boorgula MP
  2. Taub MA
  3. Rafaels N
  4. Daya M
  5. Campbell M
  6. Chavan S
  7. Shetty A
  8. Cheadle C
  9. Barkataki S
  10. Fan J
  11. David G
  12. Beaty TH
  13. Ruczinski I
  14. Hanifin J
  15. Schneider LC
  16. Gallo RL
  17. Paller AS
  18. Beck LA
  19. Leung DY
  20. Mathias RA
  21. Barnes KC
  Replicated methylation changes associated with eczema herpeticum and allergic response.; Clinical epigenetics; Vol 11(1). 2019 Aug 23.
• 1. Brewer MG
  2. Yoshida T
  3. Kuo FI
  4. Fridy S
  5. Beck LA
  6. De Benedetto A
  Antagonistic Effects of IL-4 on IL-17A-Mediated Enhancement of Epidermal Tight Junction Function.; International journal of molecular sciences; Vol 20(17). 2019 Aug 21.
• 1. Wollenberg A
  2. Beck LA
  3. Blauvelt A
  4. Simpson EL
  5. Chen Z
  6. Chen Q
  7. Shumel B
  8. Khokhar FA
  9. Hultsch T
  10. Rizova E
  11. Rossi AB
  12. Graham NMH
  13. Pirozzi G
  14. Lu Y
  15. Ardeleanu M
  Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).; The British journal of dermatology. 2019 Aug 13.
• 1. Brewer MG
  2. Anderson EA
  3. Pandya RP
  4. De Benedetto A
  5. Yoshida T
  6. Hilimire TA
  7. Martinez-Sobrido L
  8. Beck LA
  9. Miller BL
  Peptides Derived from the Tight Junction Protein, Claudin-1, Disrupt Skin Barrier and Promote Responsiveness to an Epicutaneous Vaccine.; The Journal of investigative dermatology. 2019 Aug 02.
• 1. Deleuran M
  2. Thaçi D
  3. Beck LA
  4. de Bruin-Weller M
  5. Blauvelt A
  6. Forman S
  7. Bissonnette R
  8. Reich K
  9. Soong W
  10. Hussain I
  11. Foley P
  12. Hide M
  13. Bouaziz JD
  14. Gelfand JM
  15. Sher L
  16. Schuttelaar MLA
  17. Wang C
  18. Chen Z
  19. Akinlade B
  20. Gadkari A
  21. Eckert L
  22. Davis JD
  23. Rajadhyaksha M
  24. Staudinger H
  25. Graham NMH
  26. Pirozzi G
  27. Ardeleanu M
  Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study.; Journal of the American Academy of Dermatology. 2019 Jul 30.